Results 11 to 20 of about 115,882 (349)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis [PDF]

Annals of Clinical and Translational Neurology, 2020
Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
De Bleecker, Jan, Howard, JF, Mantegazza, R, O'Brien, FL, study group, REGAIN, Yountz, M   +5 more
core   +5 more sources

Serum fibrinogen is not elevated in patients with myasthenia gravis [PDF]

Scientific Reports
Myasthenia gravis (MG) is an autoimmune, autoantibody-mediated disease characterized by fatigable weakness of skeletal muscles. MG is a heterogeneous disease that currently lacks a robust biomarker for diagnosing all subtypes.
Taylor A. Bauman, Sean M. Lee, Vern C. Juel, Yingkai Li, Karli Gilbert, Jiaxin Chen, Henry J. Kaminski, Linda L. Kusner, MGNet Investigators   +8 more
doaj   +2 more sources

Determinants of quality of life in Brazilian patients with myasthenia gravis [PDF]

Clinics, 2016
OBJECTIVES: The aims of the current study were 1) to evaluate the reliability and validity of the Brazilian version of the 15-item Myasthenia Gravis Quality of Life Scale and 2) to investigate the quality of life of Brazilian patients with myasthenia ...
Barbosa, Luiz Sergio Mageste, Comini-Frota, Elizabeth Regina, Freitas, Denise da Silva, Gomez, Rodrigo Santiago, Kummer, Arthur, Lemos, Stella Maris Aguiar, Mourão, Aline Mansueto, Teixeira, Antonio Lucio   +7 more
core   +5 more sources

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone [PDF]

Discover Oncology
Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical ...
Shanshan Gu, Xu Wang, Hongxia Yang, Yaxuan Wang, Congya Yan, Xiaoting Lin, Peng Liu, Lu Liu, Li Meng, Guoyan Qi   +9 more
doaj   +2 more sources

Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America [PDF]

BMJ Open, 2020
OBJECTIVES: To approximate the rate of familial myasthenia gravis and the coexistence of other autoimmune disorders in the patients and their families. DESIGN: Retrospective cohort study. SETTING: Clinics across North America.
et al,, Florence, Julaine, Green, Joshua D, Pestronk, Alan, Wulf, Charlie   +4 more
core   +4 more sources

Light Sensitivity in Myasthenia Gravis: Clinical Characteristics and Impact on Quality of Life [PDF]

Muscle &Nerve, Volume 71, Issue 6, Page 1081-1085, June 2025.
ABSTRACT Introduction/Aims Light sensitivity is occasionally reported in myasthenia gravis patients, yet its prevalence, clinical characteristics, and impact on disease severity and quality of life remain insufficiently explored. This study aimed to evaluate the frequency, clinical characteristics, and the correlation of light sensitivity with ...
Eleonora Sabatelli, Luca Bonagura, Silvia Falso, Sofia Marini, Claudia Papi, Lucia Campetella, Michela Myriam De Maio, Raffaele Iorio   +7 more
wiley   +2 more sources

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Journal of Neurology, 2023
Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
A. Meisel, D. Annane, T. Vu, R. Mantegazza, M. Katsuno, R. Aguzzi, G. Frick, L. Gault, J. Howard   +8 more
semanticscholar   +1 more source

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

JAMA Neurology, 2022
This randomized clinical trial investigates the efficacy and safety of rituximab compared vs placebo as an add-on with standard of care for myasthenia gravis.
F. Piehl, Ann Eriksson-Dufva, A. Budzianowska, Amalia Feresiadou, William Hansson, M. A. Hietala, I. Håkansson, Rune Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. Punga, R. Press, K. Samuelsson, P. Sundström, O. Wickberg, S. Brauner, T. Frisell   +20 more
semanticscholar   +1 more source

Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations

Journal of Clinical Medicine, 2021
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 ...
L. Dresser, R. Wlodarski, K. Rezania, B. Soliven   +3 more
semanticscholar   +1 more source

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study

Proceedings of the National Academy of Sciences of the United States of America, 2022
Significance Our study, involving 1,873 patients and 36,370 healthy individuals, is an extensive genome-wide study of myasthenia gravis. Our genome-wide association and transcriptome-wide association analyses identified two signals, namely CHRNA1 and ...
Ruth Chia, S. Sáez-Atienzar, N. Murphy, A. Chiò, C. Blauwendraat, R. Roda, P. Tienari, H. Kaminski, R. Ricciardi, M. Guida, A. De Rosa, L. Petrucci, A. Evoli, C. Provenzano, D. Drachman, B. Traynor   +15 more
semanticscholar   +1 more source